title: Authors' Reply.
authors.affiliation: Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Japan. hirakawa@med.nagoya-u.ac.jp.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Hirakawa
authors.affiliation: Biostatistics Group, Office of New Drug V, Pharmaceuticals and Medical Devices Agency, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sato
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D006801:Humans; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy*